Eli Lil­ly wraps up fifth and fi­nal tirzepatide PhI­II tri­al, claim­ing a win over Sanofi's Lan­tus. The FDA awaits

Eli Lil­ly has long been test­ing its ex­per­i­men­tal tirzepatide can­di­date in di­a­betes, look­ing to see whether or not it can take over Trulic­i­ty’s di­a­betes man­tle once the patent runs out in 2027. And on Thurs­day, the Big Phar­ma wrapped up its last reg­is­tra­tional tri­al.

Mea­sur­ing the dual GIP and GLP-1 re­cep­tor ag­o­nist tirzepatide against Sanofi’s Lan­tus in­sulin self-in­jec­tion, Lil­ly re­port­ed Thurs­day that its pro­gram hit all pri­ma­ry and key sec­ondary end­points across three dosage lev­els in adult type 2 di­a­betes pa­tients with in­creased car­dio­vas­cu­lar risk. The study was deemed com­plet­ed when enough ma­jor CV events oc­curred, and even though the end­points were eval­u­at­ed at 52 weeks, many par­tic­i­pants re­mained on treat­ment for up to two years, Lil­ly said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER